A detailed history of American Century Companies Inc transactions in Alector, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 63,838 shares of ALEC stock, worth $164,063. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,838
Previous 50,083 27.46%
Holding current value
$164,063
Previous $227,000 31.28%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.34 - $6.58 $59,696 - $90,507
13,755 Added 27.46%
63,838 $298,000
Q2 2024

Aug 07, 2024

SELL
$4.19 - $6.23 $89,439 - $132,985
-21,346 Reduced 29.88%
50,083 $227,000
Q1 2024

May 14, 2024

SELL
$5.69 - $8.08 $6,566 - $9,324
-1,154 Reduced 1.59%
71,429 $430,000
Q4 2023

Feb 13, 2024

BUY
$3.77 - $8.39 $273,637 - $608,971
72,583 New
72,583 $579,000
Q3 2023

Nov 13, 2023

SELL
$5.2 - $8.77 $148,480 - $250,418
-28,554 Reduced 27.4%
75,669 $490,000
Q2 2023

Aug 14, 2023

SELL
$5.86 - $7.93 $580,837 - $786,013
-99,119 Reduced 48.74%
104,223 $626,000
Q1 2023

May 11, 2023

SELL
$5.85 - $9.84 $757,680 - $1.27 Million
-129,518 Reduced 38.91%
203,342 $1.26 Million
Q4 2022

Feb 13, 2023

BUY
$6.88 - $9.55 $41,892 - $58,149
6,089 Added 1.86%
332,860 $3.07 Million
Q3 2022

Nov 14, 2022

BUY
$8.19 - $13.2 $1.51 Million - $2.44 Million
184,488 Added 129.66%
326,771 $3.09 Million
Q2 2022

Aug 12, 2022

BUY
$7.65 - $14.24 $10,679 - $19,879
1,396 Added 0.99%
142,283 $1.45 Million
Q1 2022

May 11, 2022

BUY
$13.02 - $20.78 $840,948 - $1.34 Million
64,589 Added 84.65%
140,887 $2.01 Million
Q4 2021

Feb 07, 2022

BUY
$19.35 - $25.54 $1.48 Million - $1.95 Million
76,298 New
76,298 $1.58 Million

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $212M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.